Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
May 18, 2016 NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with prim...
May 5, 2016 NEW YORK, May 05, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today reported financial results for the quarter ended March 3...
Apr 28, 2016 NEW YORK, April 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report first quarter 2016 financial results after the NASDAQ ...
Apr 16, 2016 NEW YORK, April 16, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the winners of its Practice to Policy Health Awards Prog...
Apr 14, 2016 NEW YORK, April 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the results of two new analyses of the POISE trial, the Phase 3 trial of ...
Apr 7, 2016 PDUFA Date is May 29, 2016 Intercept to host investor conference call today at 5:30 p.m. ET NEW YORK, April 07, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical ...
Mar 30, 2016 NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that multiple abstracts evaluating obeticholic acid (OCA) in patients with ...
Mar 16, 2016 NEW YORK, March 16, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced a new research initiative with the University of Pennsylvania's PennCHOP ...
Feb 23, 2016 NEW YORK, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today reported financial results for the fourth quarter and full year ende...
Feb 17, 2016 NEW YORK, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its fourth quarter and full year 2015 financial results pri...
Page:
1
... NextLast
= add release to Briefcase